Latest On Progenics Pharmaceuticals, Inc (PGNX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2020-12-04 08:41 EST | News | Lantheus to sell its Puerto Rico PET, radiopharmacy facilities to PharmaLogic | N/A |  |
| 2020-09-30 13:55 EST | News | Lantheus files U.S. application for PET imaging agent for prostate cancer | N/A | |
| 2020-09-26 13:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 05:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 09:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 13:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 17:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 05:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 13:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 18:06 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 09:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-07 13:36 EST | Analyst Rating | The Analyst Target Price has decreased from $6.75 to $6.5. | Neutral | |
| 2020-07-01 17:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-23 17:28 EST | Insider Trade | Bradley L Campbell has directly disposed of 12,000 shares and currently holds 0 shares. | Sell | |
| 2020-06-23 17:28 EST | Insider Trade | Gerard Ber has directly disposed of 50,000 shares and currently holds 0 shares. | Sell | |
| 2020-06-23 17:27 EST | Insider Trade | Vivien Wong has directly disposed of 4,121 shares and currently holds 0 shares. | Sell | |
| 2020-06-23 17:27 EST | Insider Trade | Benedict Osorio has directly disposed of 21,202 shares and currently holds 0 shares. | Sell | |
| 2020-06-19 13:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-17 16:03 EST | News | Lantheus shareholders back stock issuance in Progenics tie-up | N/A | |
| 2020-06-14 05:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 05:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-02 01:31 EST | Earnings Estimate | An EPS average of -$0.23 is estimated for the quarter ending on September 30, 2020. | Sell | |
| 2020-05-27 05:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-08 13:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-07 11:47 EST | News | Progenics Pharmaceuticals EPS beats by $0.03, misses on revenue | N/A | |
| 2020-05-07 11:46 EST | News | Progenics Pharmaceuticals' (PGNX) CEO David Mims on Q1 2020 Results - Earnings Call Transcript | N/A | |
| 2020-05-06 05:59 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-01 05:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-12 08:29 EST | News | Progenics up 11% on improved merger terms with Lantheus | N/A | |
| 2020-04-12 08:09 EST | News | Progenics Pharmaceuticals EPS beats by $0.12, beats on revenue | N/A | |
| 2020-04-03 21:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-20 21:17 EST | Analyst Rating | The Analyst Target Price has decreased from $7.83 to $6.75. | Neutral | |
| 2020-03-16 05:18 EST | Earnings Estimate | An EPS average of -$0.50 is estimated for the 2021 year. | Sell | |
| 2020-03-16 05:18 EST | Earnings Estimate | An EPS average of -$0.24 is estimated for the quarter ending on June 30, 2020. | Sell | |
| 2020-03-14 21:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-28 04:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-28 04:43 EST | Earnings | Earnings have been released on March 14, 2019, with -$0.17 earnings per share. | Sell | |
| 2020-02-28 04:43 EST | Earnings | Earnings have been released on March 9, 2017, with -$0.10 earnings per share. | Buy | |
| 2020-02-27 22:07 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-22 00:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-18 04:14 EST | Analyst Rating | The Analyst Target Price has decreased from $9.38 to $7.83. | Neutral | |
| 2020-02-18 00:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-17 14:43 EST | News | Progenics: Ready To Decouple From Lantheus After PyL Data | N/A | |
| 2020-02-13 04:10 EST | Analyst Rating | The Analyst Target Price has decreased from $10.33 to $9.38. | Neutral | |
| 2020-02-13 00:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-12 10:06 EST | Analyst Rating | The Analyst Target Price has increased from $9.38 to $10.33. | Buy | |
| 2020-02-07 00:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-01 00:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-01-29 00:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-01-28 04:45 EST | Earnings | Earnings have been released on November 7, 2019, with -$0.22 earnings per share. | Buy | |
About Progenics Pharmaceuticals, Inc (PGNX):
Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.
General
- Name Progenics Pharmaceuticals, Inc
- Symbol PGNX
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 105
- Fiscal Year EndDecember
- IPO Date1997-11-19
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.progenics.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 9.55
- Price/Book (Most Recent Quarter) 11.6
- Enterprise Value Revenue 10.24
View More
Financials
- Most Recent Quarter 2020-03-31
- Current Year EPS Estimate -$0.90
- Next Year EPS Estimate -$0.65
- Profit Margin -180%
- Operating Margin -166%
- Return on Assets -29%
- Return on Equity -117%
- Revenue 36.95 million
- Earnings Per Share -$0.93
- Revenue Per Share $0.43
- Gross Profit 31.82 million
- Quarterly Earnings Growth 45.9%
View More
Highlights
- Market Capitalization 355.05 million
- EBITDA -57739000
- PEG Ratio -0.03
- Analyst Target Price $6.5
- Book Value Per Share $0.35
View More
Share Statistics
- Shares Outstanding 86.6 million
- Shares Float 68.1 million
- % Held by Insiders 960%
- % Held by Institutions 76.1%
- Shares Short 5.76 million
- Shares Short Prior Month 5.83 million
- Short Ratio 9.3
- Short % of Float 9%
- Short % of Shares Outstanding 7%
View More
Technicals
- Beta 1.98
- 52 Week High $6.22
- 52 Week Low $1.89
- 50 Day Moving Average 4.33
- 200 Day Moving Average 4.14
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
View More
Progenics Pharmaceuticals, Inc (PGNX) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Progenics Pharmaceuticals, Inc (PGNX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-03-31 | 2020-05-07 | $N/A | -$0.19 | -$0.22 | 13.64% |
| 2019-12-31 | 2020-03-13 | $15.13 million | -$0.13 | -$0.20 | 35% |
| 2019-09-30 | 2019-11-07 | $5.61 million | -$0.22 | -$0.24 | 8.33% |
| 2019-06-30 | 2019-08-09 | $9.97 million | -$0.23 | -$0.19 | -21.05% |
| 2019-03-31 | 2019-05-09 | $4.28 million | -$0.22 | -$0.19 | -15.79% |
| 2018-12-31 | 2019-03-14 | $3.24 million | -$0.17 | -$0.11 | -54.55% |
| 2018-09-30 | 2018-11-08 | $5.32 million | -$0.30 | -$0.18 | -66.67% |
| 2018-06-30 | 2018-07-31 | $3.88 million | -$0.20 | -$0.19 | -5.26% |
| 2018-03-31 | 2018-05-09 | $3.19 million | -$0.19 | -$0.21 | 9.52% |
| 2017-12-31 | 2018-03-08 | $6.65 million | -$0.04 | -$0.23 | 82.61% |
| 2017-09-30 | 2017-11-02 | $2.7 million | -$0.22 | -$0.23 | 4.35% |
| 2017-06-30 | 2017-08-09 | $2.77 million | -$0.24 | -$0.21 | -14.29% |
| 2017-03-31 | 2017-05-04 | $2.35 million | -$0.23 | -$0.18 | -27.78% |
| 2016-12-31 | 2017-03-09 | $4.65 million | -$0.10 | -$0.20 | 50% |
| 2016-09-30 | 2016-11-07 | $53.85 million | $0.52 | $0.55 | -5.45% |
| 2016-06-30 | 2016-08-04 | $8.48 million | -$0.08 | -$0.13 | 38.46% |
| 2016-03-31 | 2016-05-05 | $2.45 million | -$0.18 | -$0.12 | -50% |
| 2015-12-31 | 2016-03-11 | $5.1 million | -$0.10 | -$0.14 | 28.57% |
| 2015-09-30 | 2015-11-09 | $1.4 million | -$0.14 | -$0.12 | -16.67% |
| 2015-06-30 | 2015-08-06 | $1.94 million | -$0.17 | -$0.14 | -21.43% |
| 2015-03-31 | 2015-05-06 | $248000 | -$0.15 | -$0.15 | 0% |
| 2014-12-31 | 2015-03-16 | $-571000 | -$0.18 | -$0.13 | -38.46% |
| 2014-09-30 | 2014-11-07 | $41.66 million | $0.51 | -$0.15 | 440% |
| 2014-06-30 | 2014-08-08 | $1.48 million | -$0.17 | -$0.14 | -21.43% |
| 2014-03-31 | 2014-05-09 | $1.82 million | -$0.15 | -$0.15 | 0% |
| 2013-12-31 | 2014-03-13 | $2.97 million | -$0.14 | -$0.19 | 26.32% |
| 2013-09-30 | 2013-11-11 | $867000 | -$0.17 | -$0.21 | 19.05% |
| 2013-06-30 | 2013-08-09 | $1.8 million | -$0.24 | -$0.23 | -4.35% |
| 2013-03-31 | 2013-05-10 | $2.23 million | -$0.22 | -$0.19 | -15.79% |
| 2012-12-31 | 2013-03-15 | $8.89 million | -$0.01 | -$0.31 | 96.77% |
| 2012-09-30 | 2012-11-08 | $1.12 million | -$0.33 | -$0.30 | -10% |
| 2012-06-30 | 2012-08-09 | $1.82 million | -$0.32 | -$0.32 | 0% |
| 2012-03-31 | 2012-05-08 | $2.23 million | -$0.39 | -$0.33 | -18.18% |
| 2011-12-31 | 2012-03-15 | $2.2 million | -$0.32 | -$0.29 | -10.34% |
| 2011-09-30 | 2011-11-09 | $5.8 million | -$0.34 | -$0.35 | 2.86% |
| 2011-06-30 | 2011-08-09 | $74.41 million | $1.64 | -$0.25 | 756% |
| 2011-03-31 | 2011-05-10 | $2.39 million | -$0.69 | -$0.51 | -35.29% |
| 2010-12-31 | 2011-03-15 | $2.16 million | -$0.57 | -$0.57 | 0% |
| 2010-09-30 | 2010-11-08 | $1.97 million | -$0.52 | -$0.56 | 7.14% |
| 2010-06-30 | 2010-08-09 | $2.31 million | -$0.47 | -$0.54 | 12.96% |
| 2010-03-31 | 2010-05-10 | $1.52 million | -$0.58 | -$0.41 | -41.46% |
| 2009-12-31 | 2010-03-15 | $17.16 million | -$0.02 | -$0.15 | 86.67% |
| 2009-09-30 | 2009-11-09 | $5.42 million | -$0.41 | -$0.44 | 6.82% |
| 2009-06-30 | 2009-08-06 | $5.47 million | -$0.49 | -$0.51 | 3.92% |
| 2009-03-31 | 2009-05-11 | $20.9 million | -$0.06 | -$0.28 | 78.57% |
| 2008-12-31 | 2009-03-13 | $6.83 million | -$0.49 | -$0.21 | -133.33% |
| 2008-09-30 | 2008-11-10 | $17.5 million | -$0.41 | -$0.28 | -46.43% |
| 2008-06-30 | 2008-08-08 | $28.58 million | -$0.08 | -$0.08 | 0% |
| 2008-03-31 | 2008-05-09 | $14.76 million | -$0.52 | -$0.47 | -10.64% |
| 2007-12-31 | 2008-03-17 | $15.53 million | -$0.53 | -$0.49 | -8.16% |
| 2007-09-30 | 2007-11-08 | $17.02 million | -$0.58 | -$0.34 | -70.59% |
| 2007-06-30 | 2007-08-08 | $25.46 million | -$0.09 | -$0.15 | 40% |
| 2007-03-31 | 2007-05-09 | $17.64 million | -$0.40 | -$0.14 | -185.71% |
| 2006-12-31 | 2007-03-15 | $21.93 million | -$0.07 | -$0.08 | 12.5% |
| 2006-09-30 | 2006-11-09 | $17.85 million | -$0.11 | -$0.12 | 8.33% |
| 2006-06-30 | 2006-08-08 | $19.12 million | -$0.56 | -$0.17 | -229.41% |
| 2006-03-31 | 2006-05-09 | $11 million | -$0.10 | -$0.27 | 62.96% |
| 2005-12-31 | 2006-03-15 | $2.05 million | -$1.34 | -$0.50 | -168% |
| 2005-09-30 | 2005-11-07 | $2.77 million | -$0.49 | -$0.60 | 18.33% |
| 2005-06-30 | 2005-08-09 | $2.08 million | -$0.65 | -$0.68 | 4.41% |
| 2005-03-31 | 2005-05-10 | $2.59 million | -$0.76 | -$0.64 | -18.75% |
| 2004-12-31 | 2005-03-16 | $3.29 million | -$0.60 | -$0.67 | 10.45% |
| 2004-09-30 | 2004-11-09 | $2.36 million | -$0.63 | -$0.65 | 3.08% |
| 2004-06-30 | 2004-08-09 | $2.18 million | -$0.64 | -$0.59 | -8.47% |
| 2004-03-31 | 2004-05-07 | $1.75 million | -$0.61 | -$0.61 | 0% |
| 2003-12-31 | 2004-03-15 | $2.09 million | -$0.66 | -$0.60 | -10% |
| 2003-09-30 | 2003-10-31 | $1.7 million | -$0.56 | -$0.59 | 5.08% |
| 2003-06-30 | 2003-07-30 | $1.7 million | -$0.61 | -$0.52 | -17.31% |
| 2003-03-31 | 2003-05-15 | $1.97 million | -$0.48 | -$0.56 | 14.29% |
| 2002-12-31 | 2003-03-31 | $2.32 million | -$0.56 | -$0.48 | -16.67% |
| 2002-09-30 | 2002-11-04 | $2.74 million | -$0.51 | -$0.44 | -15.91% |
| 2002-06-30 | 2002-08-07 | $2.65 million | -$0.43 | -$0.41 | -4.88% |
| 2002-03-31 | 2002-05-10 | $2.37 million | -$0.16 | -$0.30 | 46.67% |
| 2001-12-31 | 2002-03-13 | $1.26 million | -$0.36 | -$0.31 | -16.13% |
| 2001-09-30 | 2001-10-31 | $1.39 million | -$0.25 | -$0.33 | 24.24% |
| 2001-06-30 | 2001-08-06 | $1.29 million | $0.38 | $0.26 | 46.15% |
| 2001-03-31 | 2001-05-15 | $4.94 million | $0.03 | -$0.18 | 116.67% |
| 2000-12-31 | 2001-03-21 | $2.48 million | -$0.20 | -$0.12 | -66.67% |
| 2000-09-30 | 2000-10-26 | $2.66 million | -$0.05 | -$0.12 | 58.33% |
| 2000-06-30 | 2000-08-01 | $2.33 million | -$0.11 | -$0.14 | 21.43% |
| 2000-03-31 | 2000-05-04 | $2.35 million | -$0.12 | -$0.07 | -71.43% |
| 1999-12-31 | 2000-02-17 | $0.12 | -$0.09 | 233.33% | |
| 1999-09-30 | 1999-10-26 | $0.13 | -$0.07 | 285.71% | |
| 1999-06-30 | 1999-08-03 | -$0.35 | -$0.04 | -775% | |
| 1999-03-31 | 1999-05-05 | -$0.03 | -$0.05 | 40% | |
| 1998-12-31 | 1999-02-24 | $0.03 | -$0.08 | 137.5% | |
| 1998-09-30 | 1998-10-27 | $0.06 | $0.04 | 50% | |
| 1998-06-30 | 1998-08-04 | $0.08 | $0.01 | 700% | |
| 1998-03-31 | 1998-05-07 | -$0.02 | $0.01 | -300% | |
| 1997-12-31 | 1998-03-27 | -$0.13 | -$0.13 | 0% |
Progenics Pharmaceuticals, Inc (PGNX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 | Mar 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | 12.31 million | 11.44 million | 13.08 million | 12.39 million |
| Income Before Tax | N/A | -11.26 million | -18.84 million | -19.7 million | -18.74 million |
| Selling General Administrative | N/A | 12.57 million | 11.47 million | 14.57 million | 9.22 million |
| Gross Profit | N/A | 13.77 million | 4.3 million | 9.47 million | 4.28 million |
| Ebit | N/A | -11.12 million | -18.62 million | -18.18 million | -17.34 million |
| Operating Income | N/A | -11.12 million | -18.62 million | -18.18 million | -17.34 million |
| Income Tax Expense | N/A | 17000 | N/A | N/A | N/A |
| Total Revenue | N/A | 15.13 million | 5.61 million | 9.97 million | 4.28 million |
| Cost of Revenue | N/A | 1.36 million | 1.32 million | 493000 | N/A |
| Total Other Income Expense Net | N/A | -143000 | -226000 | -1.52 million | -1.4 million |
| Net Income From Continuing Operations | N/A | -11.28 million | -18.84 million | -19.7 million | -18.74 million |
| Net Income Applicable to Common Shares | -16.8 million | -11.28 million | -18.84 million | -19.7 million | -18.74 million |
Cash Flow:
| Date | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 | Mar 31 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | N/A |
| Change to Liabilities | N/A | N/A | N/A | -293000 | 124000 |
| Total Cash Flow from Investing Activities | N/A | N/A | N/A | -1.61 million | -8.49 million |
| Net Borrowings | N/A | N/A | N/A | -1.55 million | -1.04 million |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | -1.29 million | -1.04 million |
| Change to Operating Activities | N/A | N/A | N/A | 2.85 million | -1.39 million |
| Change in Cash | N/A | N/A | N/A | -23.03 million | -28.09 million |
| Total Cash from Operating Activities | N/A | N/A | N/A | -20.18 million | -18.52 million |
| Depreciation | N/A | N/A | N/A | 609000 | 557000 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | -277000 | -277000 |
| Change to Inventory | N/A | N/A | N/A | -2.07 million | N/A |
| Change to Account Receivables | N/A | N/A | N/A | -5.63 million | -1.14 million |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | N/A | N/A | N/A | 1.98 million | 2.06 million |
| Capital Expenditures | N/A | N/A | N/A | 1.34 million | 8.49 million |
Balance Sheet:
| Date | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 | Mar 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | 72.92 million | 74.12 million | 80.05 million | 80.83 million |
| Total Stockholder Equity | N/A | 46.55 million | 55.94 million | 72.73 million | 83.38 million |
| Other Current Liabilities | N/A | 22.07 million | 20.14 million | 20.67 million | 7.9 million |
| Total Assets | N/A | 119.47 million | 130.05 million | 152.78 million | 164.2 million |
| Common Stock | 30.61 million | 46.55 million | 55.94 million | 112000 | 110000 |
| Other Current Assets | N/A | N/A | N/A | 4.81 million | 3.13 million |
| Retained Earnings | N/A | N/A | N/A | -647.64 million | -627.94 million |
| Other Liabilities | 3.6 million | 3.9 million | 4.3 million | 4.83 million | 4.03 million |
| Other Assets | 10.28 million | 25.09 million | 11.5 million | 6.46 million | 1.7 million |
| Cash | N/A | 42.05 million | 64.49 million | 84.82 million | 109.59 million |
| Total Current Liabilities | N/A | 22.07 million | 20.14 million | 23.57 million | 24.45 million |
| Other Stockholder Equity | N/A | N/A | N/A | -1.03 million | -147000 |
| Property, Plant & Equipment | 27.95 million | 11.69 million | 22.94 million | 20.9 million | 19.36 million |
| Total Current Assets | N/A | 58.03 million | 70.67 million | 100.2 million | 117.65 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 6.22 million | 21.88 million | 30.99 million | 47.51 million | 57.88 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | 46.95 million | 34.52 million | 36.34 million | 37.57 million |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | 272000 | 564000 |
Progenics Pharmaceuticals, Inc (PGNX) Chart:
Progenics Pharmaceuticals, Inc (PGNX) News:
Below you will find a list of latest news for Progenics Pharmaceuticals, Inc (PGNX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Progenics Pharmaceuticals, Inc (PGNX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Progenics Pharmaceuticals, Inc (PGNX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-02 | 15-12G | Securities registration termination [Section 12(g)] | https://www.sec.gov/Archives/edgar/data/835887/000119312520185879/0001193125-20-185879-index.htm |
| 2019-11-29 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/835887/000000000019015954/0000000000-19-015954-index.htm |
| 2020-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/835887/000008025520001034/0000080255-20-001034-index.htm |
| 2020-02-13 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/835887/000009375120000401/0000093751-20-000401-index.htm |
| 2020-01-06 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/835887/000079050220000001/0000790502-20-000001-index.htm |
| 2020-06-04 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/835887/000079050220000009/0000790502-20-000009-index.htm |
| 2020-02-04 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/835887/000083423720002710/0000834237-20-002710-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/835887/000091957420001440/0000919574-20-001440-index.htm |
| 2019-08-26 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/835887/000092189519002331/0000921895-19-002331-index.htm |
| 2019-08-27 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000092189519002341/0000921895-19-002341-index.htm |
| 2019-08-27 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000092189519002342/0000921895-19-002342-index.htm |
| 2019-08-27 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000092189519002343/0000921895-19-002343-index.htm |
| 2019-08-27 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000092189519002344/0000921895-19-002344-index.htm |
| 2019-08-27 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000092189519002345/0000921895-19-002345-index.htm |
| 2019-08-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000092189519002346/0000921895-19-002346-index.htm |
| 2019-09-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000092189519002367/0000921895-19-002367-index.htm |
| 2019-09-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000092189519002384/0000921895-19-002384-index.htm |
| 2019-09-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000092189519002393/0000921895-19-002393-index.htm |
| 2019-09-18 | DFAN14A | Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/835887/000092189519002428/0000921895-19-002428-index.htm |
| 2019-09-19 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/835887/000092189519002436/0000921895-19-002436-index.htm |
| 2019-09-27 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000092189519002464/0000921895-19-002464-index.htm |
| 2019-09-27 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000092189519002465/0000921895-19-002465-index.htm |
| 2019-09-27 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000092189519002466/0000921895-19-002466-index.htm |
| 2019-09-27 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000092189519002467/0000921895-19-002467-index.htm |
| 2019-09-27 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000092189519002468/0000921895-19-002468-index.htm |
| 2019-09-30 | PRRN14A | Non-management revised preliminary proxy soliciting materials, contested and otherwise | https://www.sec.gov/Archives/edgar/data/835887/000092189519002473/0000921895-19-002473-index.htm |
| 2019-10-02 | DFAN14A | Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/835887/000092189519002487/0000921895-19-002487-index.htm |
| 2019-10-03 | PRRN14A | Non-management revised preliminary proxy soliciting materials, contested and otherwise | https://www.sec.gov/Archives/edgar/data/835887/000092189519002493/0000921895-19-002493-index.htm |
| 2019-10-08 | DEFC14A | Definitive proxy statement, contested solicitations | https://www.sec.gov/Archives/edgar/data/835887/000092189519002523/0000921895-19-002523-index.htm |
| 2019-10-08 | DFAN14A | Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/835887/000092189519002528/0000921895-19-002528-index.htm |
| 2019-10-11 | DFRN14A | Revised definitive proxy statement filed by non-management | https://www.sec.gov/Archives/edgar/data/835887/000092189519002541/0000921895-19-002541-index.htm |
| 2019-10-16 | DFAN14A | Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/835887/000092189519002559/0000921895-19-002559-index.htm |
| 2019-10-21 | DFAN14A | Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/835887/000092189519002578/0000921895-19-002578-index.htm |
| 2019-10-21 | DFAN14A | Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/835887/000092189519002581/0000921895-19-002581-index.htm |
| 2019-10-22 | DFAN14A | Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/835887/000092189519002583/0000921895-19-002583-index.htm |
| 2019-10-23 | DFAN14A | Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/835887/000092189519002597/0000921895-19-002597-index.htm |
| 2019-10-24 | DFAN14A | Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/835887/000092189519002601/0000921895-19-002601-index.htm |
| 2019-10-28 | DFAN14A | Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/835887/000092189519002617/0000921895-19-002617-index.htm |
| 2019-11-04 | DFAN14A | Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/835887/000092189519002660/0000921895-19-002660-index.htm |
| 2019-11-05 | DFAN14A | Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/835887/000092189519002671/0000921895-19-002671-index.htm |
| 2019-11-08 | DFAN14A | Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/835887/000092189519002693/0000921895-19-002693-index.htm |
| 2019-11-12 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/835887/000092189519002703/0000921895-19-002703-index.htm |
| 2020-04-09 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/835887/000092189520001071/0000921895-20-001071-index.htm |
| 2020-04-15 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/835887/000092189520001106/0000921895-20-001106-index.htm |
| 2020-02-11 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/835887/000110465920016359/0001104659-20-016359-index.htm |
| 2019-10-02 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312519260323/0001193125-19-260323-index.htm |
| 2019-10-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000119312519260332/0001193125-19-260332-index.htm |
| 2019-10-02 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312519260333/0001193125-19-260333-index.htm |
| 2019-10-02 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312519260403/0001193125-19-260403-index.htm |
| 2019-10-02 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312519260799/0001193125-19-260799-index.htm |
| 2019-10-02 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312519260855/0001193125-19-260855-index.htm |
| 2019-10-02 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312519260856/0001193125-19-260856-index.htm |
| 2019-10-02 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312519260863/0001193125-19-260863-index.htm |
| 2019-10-03 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312519260869/0001193125-19-260869-index.htm |
| 2019-10-04 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312519262843/0001193125-19-262843-index.htm |
| 2019-10-04 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312519262849/0001193125-19-262849-index.htm |
| 2019-10-23 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312519272164/0001193125-19-272164-index.htm |
| 2019-11-01 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312519281282/0001193125-19-281282-index.htm |
| 2019-11-07 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312519286687/0001193125-19-286687-index.htm |
| 2019-11-07 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312519286808/0001193125-19-286808-index.htm |
| 2019-11-13 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312519290217/0001193125-19-290217-index.htm |
| 2020-01-08 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312520003947/0001193125-20-003947-index.htm |
| 2020-01-10 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312520005452/0001193125-20-005452-index.htm |
| 2020-02-20 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312520043020/0001193125-20-043020-index.htm |
| 2020-02-20 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312520043686/0001193125-20-043686-index.htm |
| 2020-02-21 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312520044759/0001193125-20-044759-index.htm |
| 2020-02-26 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312520050218/0001193125-20-050218-index.htm |
| 2020-02-27 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312520053015/0001193125-20-053015-index.htm |
| 2020-03-19 | DEFM14A | Definitive proxy statement relating to merger or acquisition | https://www.sec.gov/Archives/edgar/data/835887/000119312520078399/0001193125-20-078399-index.htm |
| 2020-04-02 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312520095394/0001193125-20-095394-index.htm |
| 2020-04-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000119312520095415/0001193125-20-095415-index.htm |
| 2020-04-02 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312520095416/0001193125-20-095416-index.htm |
| 2020-04-14 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312520105932/0001193125-20-105932-index.htm |
| 2020-04-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000119312520107169/0001193125-20-107169-index.htm |
| 2020-04-14 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312520107170/0001193125-20-107170-index.htm |
| 2020-04-23 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/835887/000119312520117311/0001193125-20-117311-index.htm |
| 2020-05-07 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312520136306/0001193125-20-136306-index.htm |
| 2020-05-12 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000119312520140488/0001193125-20-140488-index.htm |
| 2020-05-14 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/835887/000119312520142345/0001193125-20-142345-index.htm |
| 2020-06-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000119312520163566/0001193125-20-163566-index.htm |
| 2020-06-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000119312520170487/0001193125-20-170487-index.htm |
| 2020-06-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000119312520171462/0001193125-20-171462-index.htm |
| 2020-06-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000119312520174778/0001193125-20-174778-index.htm |
| 2020-06-22 | POS AM | Post-Effective amendments for registration statement | https://www.sec.gov/Archives/edgar/data/835887/000119312520174794/0001193125-20-174794-index.htm |
| 2020-06-22 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/835887/000119312520174796/0001193125-20-174796-index.htm |
| 2020-06-22 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/835887/000119312520174799/0001193125-20-174799-index.htm |
| 2020-06-22 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/835887/000119312520174802/0001193125-20-174802-index.htm |
| 2020-06-22 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/835887/000119312520174807/0001193125-20-174807-index.htm |
| 2020-06-22 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/835887/000119312520174811/0001193125-20-174811-index.htm |
| 2020-06-22 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/835887/000119312520174814/0001193125-20-174814-index.htm |
| 2020-06-22 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/835887/000119312520174816/0001193125-20-174816-index.htm |
| 2020-06-23 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/835887/000119312520176191/0001193125-20-176191-index.htm |
| 2020-07-02 | 15-12G | Securities registration termination [Section 12(g)] | https://www.sec.gov/Archives/edgar/data/835887/000119312520185879/0001193125-20-185879-index.htm |
| 2019-09-18 | PREC14A | Preliminary proxy statements, contested solicitations | https://www.sec.gov/Archives/edgar/data/835887/000119380519000821/0001193805-19-000821-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/835887/000121465920001391/0001214659-20-001391-index.htm |
| 2020-06-22 | 25-NSE | Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or ret | https://www.sec.gov/Archives/edgar/data/835887/000135445720000263/0001354457-20-000263-index.htm |
| 2019-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000143774919015627/0001437749-19-015627-index.htm |
| 2019-08-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000143774919016035/0001437749-19-016035-index.htm |
| 2019-08-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000143774919016129/0001437749-19-016129-index.htm |
| 2019-08-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/835887/000143774919016232/0001437749-19-016232-index.htm |
| 2019-08-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000143774919017527/0001437749-19-017527-index.htm |
| 2019-09-19 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/835887/000143774919018654/0001437749-19-018654-index.htm |
| 2019-09-25 | PREC14A | Preliminary proxy statements, contested solicitations | https://www.sec.gov/Archives/edgar/data/835887/000143774919019003/0001437749-19-019003-index.htm |
| 2019-10-04 | PRER14A | Preliminary Proxy Soliciting materials | https://www.sec.gov/Archives/edgar/data/835887/000143774919019724/0001437749-19-019724-index.htm |
| 2019-10-08 | DEFC14A | Definitive proxy statement, contested solicitations | https://www.sec.gov/Archives/edgar/data/835887/000143774919019827/0001437749-19-019827-index.htm |
| 2019-10-10 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000143774919019875/0001437749-19-019875-index.htm |
| 2019-10-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000143774919020283/0001437749-19-020283-index.htm |
| 2019-10-21 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000143774919020339/0001437749-19-020339-index.htm |
| 2019-10-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000143774919020394/0001437749-19-020394-index.htm |
| 2019-10-22 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000143774919020395/0001437749-19-020395-index.htm |
| 2019-10-23 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000143774919020502/0001437749-19-020502-index.htm |
| 2019-10-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000143774919020504/0001437749-19-020504-index.htm |
| 2019-10-23 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000143774919020505/0001437749-19-020505-index.htm |
| 2019-10-28 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000143774919020761/0001437749-19-020761-index.htm |
| 2019-10-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000143774919020849/0001437749-19-020849-index.htm |
| 2019-10-30 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000143774919020850/0001437749-19-020850-index.htm |
| 2019-11-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000143774919021311/0001437749-19-021311-index.htm |
| 2019-11-01 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000143774919021312/0001437749-19-021312-index.htm |
| 2019-11-01 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000143774919021313/0001437749-19-021313-index.htm |
| 2019-11-05 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000143774919021520/0001437749-19-021520-index.htm |
| 2019-11-05 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/835887/000143774919021523/0001437749-19-021523-index.htm |
| 2019-11-06 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/835887/000143774919021728/0001437749-19-021728-index.htm |
| 2019-11-06 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000143774919021776/0001437749-19-021776-index.htm |
| 2019-11-06 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/835887/000143774919021777/0001437749-19-021777-index.htm |
| 2019-11-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000143774919021835/0001437749-19-021835-index.htm |
| 2019-11-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/835887/000143774919021961/0001437749-19-021961-index.htm |
| 2019-11-07 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000143774919021988/0001437749-19-021988-index.htm |
| 2019-11-08 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/835887/000143774919022193/0001437749-19-022193-index.htm |
| 2019-11-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000143774919022236/0001437749-19-022236-index.htm |
| 2019-11-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000143774919023074/0001437749-19-023074-index.htm |
| 2019-11-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000143774919023353/0001437749-19-023353-index.htm |
| 2019-12-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000143774919024666/0001437749-19-024666-index.htm |
| 2019-12-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000143774919024760/0001437749-19-024760-index.htm |
| 2020-01-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000143774920000910/0001437749-20-000910-index.htm |
| 2020-02-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000143774920003132/0001437749-20-003132-index.htm |
| 2020-02-20 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000143774920003133/0001437749-20-003133-index.htm |
| 2020-02-20 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000143774920003156/0001437749-20-003156-index.htm |
| 2020-02-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000143774920003176/0001437749-20-003176-index.htm |
| 2020-02-20 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000143774920003177/0001437749-20-003177-index.htm |
| 2020-03-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000143774920004345/0001437749-20-004345-index.htm |
| 2020-03-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000143774920005060/0001437749-20-005060-index.htm |
| 2020-03-13 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/835887/000143774920005061/0001437749-20-005061-index.htm |
| 2020-03-13 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/835887/000143774920005145/0001437749-20-005145-index.htm |
| 2020-03-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000143774920005215/0001437749-20-005215-index.htm |
| 2020-04-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000143774920006775/0001437749-20-006775-index.htm |
| 2020-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000143774920009692/0001437749-20-009692-index.htm |
| 2020-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/835887/000143774920009815/0001437749-20-009815-index.htm |
| 2020-05-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000143774920011152/0001437749-20-011152-index.htm |
| 2020-05-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000143774920011934/0001437749-20-011934-index.htm |
| 2020-06-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/835887/000143774920012911/0001437749-20-012911-index.htm |
| 2020-06-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000143774920013671/0001437749-20-013671-index.htm |
| 2020-06-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000143774920013672/0001437749-20-013672-index.htm |
| 2020-06-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000143774920013673/0001437749-20-013673-index.htm |
| 2020-06-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000143774920013674/0001437749-20-013674-index.htm |
| 2020-06-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000143774920013675/0001437749-20-013675-index.htm |
| 2020-06-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000143774920013676/0001437749-20-013676-index.htm |
| 2020-06-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000143774920013677/0001437749-20-013677-index.htm |
| 2020-06-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000143774920013678/0001437749-20-013678-index.htm |
| 2020-06-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000143774920013679/0001437749-20-013679-index.htm |
| 2020-06-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000143774920013680/0001437749-20-013680-index.htm |
| 2020-06-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000143774920013681/0001437749-20-013681-index.htm |
| 2019-12-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000156218019006143/0001562180-19-006143-index.htm |
| 2019-12-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000156218019006144/0001562180-19-006144-index.htm |
| 2019-12-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000156218019006145/0001562180-19-006145-index.htm |
| 2019-12-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000156218019006146/0001562180-19-006146-index.htm |
| 2019-12-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000156218019006147/0001562180-19-006147-index.htm |
| 2019-12-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000156218019006148/0001562180-19-006148-index.htm |
| 2019-12-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000156218019006149/0001562180-19-006149-index.htm |
| 2019-12-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000156218019006150/0001562180-19-006150-index.htm |
| 2019-12-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000156218019006151/0001562180-19-006151-index.htm |
| 2019-12-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000156218019006152/0001562180-19-006152-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000156218020002131/0001562180-20-002131-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000156218020002132/0001562180-20-002132-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000156218020002134/0001562180-20-002134-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000156218020002135/0001562180-20-002135-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/835887/000156218020002136/0001562180-20-002136-index.htm |
| 2020-06-26 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/835887/999999999520001661/9999999995-20-001661-index.htm |
Progenics Pharmaceuticals, Inc (PGNX) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Progenics Pharmaceuticals, Inc (PGNX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 960%Institutional Ownership: 7610%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-06-19 | Benedict Osorio | COO | Sell | 21,202.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/835887/000143774920013680/0001437749-20-013680-index.htm | ||
| 2020-06-19 | Bradley L Campbell | Director | Sell | 12,000.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/835887/000143774920013675/0001437749-20-013675-index.htm | ||
| 2020-06-19 | Gerard Ber | Director | Sell | 50,000.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/835887/000143774920013676/0001437749-20-013676-index.htm | ||
| 2020-06-19 | Vivien Wong | EVP, Development | Sell | 4,121.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/835887/000143774920013678/0001437749-20-013678-index.htm | ||
| 2019-09-05 | LTE Partners, LLC | 10% Share Holder | Buy | 43,520.00 | 4.62 | 201,097.22 | 1,928,520.00 | https://www.sec.gov/Archives/edgar/data/835887/000092189519002384/0000921895-19-002384-index.htm |
| 2019-09-09 | LTE Partners, LLC | 10% Share Holder | Buy | 21,480.00 | 4.94 | 106,096.16 | 1,950,000.00 | https://www.sec.gov/Archives/edgar/data/835887/000092189519002384/0000921895-19-002384-index.htm |
| 2019-08-23 | Velan Capital, L.P. | 10% Share Holder | Buy | 130,826.00 | 4.31 | 563,689.99 | 7,345,442.00 | https://www.sec.gov/Archives/edgar/data/835887/000092189519002346/0000921895-19-002346-index.htm |
| 2019-08-26 | Velan Capital, L.P. | 10% Share Holder | Buy | 73,230.00 | 4.30 | 314,910.97 | 7,418,672.00 | https://www.sec.gov/Archives/edgar/data/835887/000092189519002346/0000921895-19-002346-index.htm |
| 2019-09-03 | Velan Capital, L.P. | 10% Share Holder | Buy | 277,424.00 | 4.39 | 1,218,917.83 | 7,696,096.00 | https://www.sec.gov/Archives/edgar/data/835887/000092189519002367/0000921895-19-002367-index.htm |
| 2019-09-04 | Velan Capital, L.P. | 10% Share Holder | Buy | 243,614.00 | 4.51 | 1,098,528.61 | 7,939,710.00 | https://www.sec.gov/Archives/edgar/data/835887/000092189519002367/0000921895-19-002367-index.htm |
| 2019-09-09 | Velan Capital, L.P. | 10% Share Holder | Buy | 72,023.00 | 4.99 | 359,733.28 | 8,011,733.00 | https://www.sec.gov/Archives/edgar/data/835887/000092189519002393/0000921895-19-002393-index.htm |